A Chinese vitamin producer announced Thursday it is planning on filing an appeal of an earlier US decision that found the company, along with three others, of conspiring to fix vitamin prices in the US.
NCPC’s appeal will be the first time a Chinese pharmaceutical firm has been fined by US regulators in an antitrust case, say reports.
The US District Court for the Eastern District of New York offered the ruling November 26, ordering the Chinese firm to pay $153.3 million for the Vitamin C collusion.
Full Content: CRJEnglish
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Set to Fine Apple in First Major Enforcement of Digital Markets Act
Nov 5, 2024 by
CPI
Six Indicted in Federal Bid-Rigging Schemes Involving Government IT Contracts
Nov 5, 2024 by
CPI
Ireland Secures First €3 Billion Apple Tax Payment, Boosting Exchequer Funds
Nov 5, 2024 by
CPI
Italy’s Data Protection Authority Criticizes Intesa’s Handling of Customer Data
Nov 5, 2024 by
CPI
Italy Halts Sale of ITA Airways Stake to Lufthansa Amid Price Dispute
Nov 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI